Aditxt Stock (NASDAQ:ADTX)


ForecastRevenueOwnershipFinancialsChart

Previous Close

$1.60

52W Range

$1.28 - $548.00

50D Avg

$27.80

200D Avg

$95.97

Market Cap

$200.73K

Avg Vol (3M)

$923.44K

Beta

0.94

Div Yield

-

ADTX Company Profile


Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

47

IPO Date

Jun 30, 2020

Website

ADTX Performance


ADTX Financial Summary


Dec 23Dec 22Dec 21
Revenue$645.18K$933.72K$105.03K
Operating Income$-26.06M$-24.94M$-27.43M
Net Income$-32.38M$-28.19M$-48.31M
EBITDA$-25.52M$-24.28M$-26.96M
Basic EPS$-107.10$-608.04$-5.06K
Diluted EPS$-107.10$-608.04$-5.06K

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison


TickerCompany
BDRXBiodexa Pharmaceuticals Plc
BWVOnconetix, Inc.
PXMDPaxMedica, Inc. Common Stock
REVBRevelation Biosciences, Inc.
QNRXQuoin Pharmaceuticals, Ltd.
HILSTharimmune, Inc.
DRMADermata Therapeutics, Inc.
VRAXVirax Biolabs Group Limited
ALLRAllarity Therapeutics, Inc.
NRBONeuroBo Pharmaceuticals, Inc.
UNCYUnicycive Therapeutics, Inc.
PSTVPlus Therapeutics, Inc.
PALIPalisade Bio, Inc.